Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Fernandez Marrero, Yuniel; Spinner, S; Jost, P J; Kaufmann, Thomas (2016). Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia, 30(11), pp. 2152-2159. Nature Publishing Group 10.1038/leu.2016.213

Text Kaufmann_Fernandez_Survival control of malignant lymphocytes by antiapotic MCL.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (473kB)

Programmed apoptotic cell death is critical to maintain tissue homeostasis and cellular integrity in the lymphatic system. Accordingly, the evasion of apoptosis is a critical milestone for the transformation of lymphocytes on their way to becoming overt lymphomas. The anti-apoptotic BCL-2 family proteins are pivotal regulators of the mitochondrial apoptotic pathway and genetic aberrations in these genes are associated with lymphomagenesis and chemotherapeutic resistance. Pharmacological targeting of BCL-2 is highly effective in certain indolent B-cell lymphomas; however, recent evidence highlights a critical role for the BCL-2 family member MCL-1 in several lymphoma subtypes. MCL-1 is recurrently highly expressed in various kinds of cancer including non-Hodgkin's lymphoma of B- and T-cell origin. Moreover, both indolent and aggressive forms of lymphoma require MCL-1 for lymphomagenesis and for their continued survival. This review summarizes the role of MCL-1 in B- and T-cell lymphoma and discusses its potential as a therapeutic target.Leukemia advance online publication, 2 September 2016; doi:10.1038/leu.2016.213.

Interest & Impact

Downloads

7 since deposited on 09 Nov 2016
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item